A series of launches of targeted antibodies has enlarged the patient selection

As a series of anticancer drugs targeting a specific disease has acquired product approvals, it is expected that patients will have a larger choice. 

Recently, Ono Pharmaceutical Korea has acquired a product approval for its PD-1 targeted antibody (indication for melanoma therapy) ‘Opdivo 20mg and 100mg (nivolumab).’

The drug was approved for treating melanoma, which is metastatic or impossib...